Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

BasicB....doc

4,582 views

Published on

Published in: Economy & Finance, Business
  • Be the first to comment

  • Be the first to like this

BasicB....doc

  1. 1. October 2002 Prepared by The Investment Promotion Center Telephone: +972 2-6222061 Fax: +972 2-6222412 Email: maxli@moit.gov.il
  2. 2. Table of Contents Letter from Max Livnat, Director of Investment Promotions____________3 Three Reasons to Invest in Israeli Biotechnology_____________________4 Prof. Michel Rivel on Israeli Biotechnology ________________________6 Biotechnology in Israel: Securing a Prominent Place on World Markets___________________________________9 Biotechnology at Israel’s Universities____________________________12 A Comprehensive list of Israel’s Biotechnology Companies: Therapeutic___________________________________________16 Agro-Bio ___________________________________________ 113 Biotechnology Incubators in Israel_____________________________190 Academic Research and Development Institutions________________202 2
  3. 3. MINISTRY OF INDUSTRY & TRADE DIRECTOR OF INVESTMENT PROMOTION CENTER I have much pleasure to send to you a briefing book prepared by the Investment Promotion Center regarding the Israel Biotech Industry. Israel is considered one of the leading countries in the world in the field of biotechnology. In 1980 there were only 4 companies in that field and in 2002 there are more than 160 companies. There are more than 900 senior faculty members in biotech related departments at the Israeli universities involved in 800 research projects. 13 of Israelis’ PhDs are in biotechnology and no less than 35% of the academic budget research is devoted to life science. About 4500 highly skilled scientists are involved in biotechnology and this number is expected to increase to 10,000 in the year 2010. Israel biotech sales reached an amount of 800 million $ in the year 2000 and are expected to reach 1.8 billion $ in the year 2003. In 2001 16% of the capital raised by venture capital companies was in life science. Israel biotech is especially strong in therapeutics, Agro- biotechnology and diagnostics. In therapeutics the main fields of research are in Neurology, Autoimmune Disorders and Anti-Cancer. Most of the Israeli companies are small and mediums sized and are looking for cooperation with foreign corporations in order to develop strategic alliances and establish joint research and development centers in Israel. I do hope that you may find interest in the briefing book and we do remain at your disposal for any further information and assistance. Sincerely, Max Livnat Senior Deputy Director General Director, Investment Promotion Center 3
  4. 4. Three Reasons to Invest in Israel Outstanding Human Resources •1 Israel boasts 140 scientists and technicians per 10,000 workers – more than any other developed nation in the world •2 Israel has more senior faculty members per million inhabitants than any other nation, including the United States and Great Britain •3 Israel trails only the United States in Publications in Leading Life Science Magazines per 100,000 inhabitants; it has more articles published than the UK, Germany and Canada •4 35% of Israelis between the ages of 25-64 have university degrees (third in the industrialized world behind the US and the Netherlands); more than 40% of the 1 million immigrants from the former Soviet Union hold advanced academic degrees; 77% of the population hold high school diplomas •5 Highly trained graduates of the Israel Defense Forces have spearheaded the high-tech boom, transferring defense technology into the civilian marketplace Modern Infrastructure for Biotechnology Development •1 World class educational institutions such as the Technion, the Weizmann Institute for Science, the Hebrew University of Jerusalem, Ben Gurion University in the Negev, Haifa University, Bar-Ilan University and Tel Aviv University •2 Well established multinationals such as Intel, Motorola, Daimler Chrysler, IBM and Microsoft •3 Over 100 Israeli companies publicly traded on Wall Street (more than any other country outside North America) •4 State of the art telecommunications and data communications systems •5 Free trade agreements with the US, EU, Turkey, Canada, Czech Republic, Slovak Republic, Hungary, Poland, Slovenia and other EFTA nations •6 Over 80 venture capital funds ready to assist new business development 4
  5. 5. •7 Treaties preventing double taxation with advanced nations •8 Relaxed currency regulations •1 Active and sophisticated capital markets •2 Comprehensive protection of trademarks, patents and intellectual property Generous Government Support • Significant government funding of R&D projects • Government grants for foreign investments • Tax holidays of up to 10 years • Binational funds granted to R&D projects between partners in Israel and participating countries, i.e. US, EU, Singapore, etc… • The Office of the Chief Scientist supports 26 technological incubators, including two new biotechnology incubators 5
  6. 6. Biotechnology in Israel By Professor Michel Revel, Department of Molecular Genetics, Weizmann Institute of Science and Chairman of Israel’s National Committee for Biotechnology Following the successes of its science-based industry in electronics, software and communications, Israel has a strong potential to take a leading place in the world of Biotechnology. Israel ranks as a top country for scientific publications per capita and almost 60% of its scientific publications are in biology and related medical or agricultural fields. Life sciences represent about 35% of Israel civilian research activities, mainly in its 7 universities, 5 medical schools and for agricultural research at the Volcani Institute and the Hebrew University Faculty of Agriculture. In Biotechnology, strong basic research is a prerequisite for industrial applications, so that both research and transition to industry are in need of support form government and from university structures such as R&D commercialization offices (e.g. Yeda at the Weizmann Institute, Yissum at the Hebrew University or Ramot at Tel Aviv University). Many scientists from Academic Institutions have taken positions in Biotech Industries. From the 3-4 young Biotech companies in 1980, Israel has grown in 2000 to around 160 industrial enterprises active in the various sectors of Therapeutic pharmaceuticals, Diagnostics, Bio-informatics and Agro-Bio including plant and farm animal products. The Biotech work force grew from 400 in 1988 to 4,000 today. Sales of products developed by the Israeli Biotech sector, which were 15 M$ in 1988, reached 600 M$ in 1999, about 80% being exported. The share of Israel is about 2.5% of the total world Biotechnology sales. Biotechnology contributed significantly to the growth of the Israeli Medical industry, including medical equipment and electronics as well as generic drugs, whose exports were 1.1 B$ in 1998, over 5% of the total Israeli exports. Therapeutic Pharmaceuticals amount to 67% of the Israeli Biotech product sales. InterPharm developed and manufactures recombinant Interferon-beta (Rebif) and other cytokines by a proprietary technology expressing human genes in mammalian cell cultures. 6
  7. 7. InterPharm is a subsidiary of Ares-Serono, which registered and markets Rebif for treatment of Multiple Sclerosis in 40 countries. A different drug for Multiple Sclerosis, Copaxone is produced and sold by Teva in the USA and worldwide. Biotechnology General sells recombinant Growth Hormone, a Hepatitis B vaccine and viscoelastics for joints and eye applications. Pharmos registered in the USA new opthalmic drugs and develops medication for strokes and head traumas. Many other products are under development including drug delivery systems (D-Pharm, Omri), human monoclonal anti bodies (XTL Pharmaceuticals), structurally shapes peptides (Peptor), recombinant heparanase (Insight) and cell therapies promising for spinal cord traumas (Proneuron). With a number of start-ups, this sector counts 36 companies. Platform technology companies, especially in Genomic Bio-informatics (Compugen, QBI) and in computer- aided molecular design (Synergics, Peptor, BTG, Green Care), develop new drug generations. The world market of therapeutic gene products, many of which will derive from the human genome project, is very high. Erythropoietin, GM-CSF, Inteferon reach $2 billion per year; Interferon for Multiple Sclerosis reaches $1.2 billion in 1999 with 170,000 patients treated. It would be enough for Israeli Companies to develop 2-3 new such drugs, but the length and costs of clinical trials has until now required to incorporate into multinationals. For diagnostics, developments are less financially demanding, but the market is also more limited. In Israel, Diagnostics amount to 4% of Biotech sales, mainly from genetic and immunological assays for viruses and other pathogens (Orgenics, Savyon, Rahan Meristem, Gamida-Gen). But genetic diagnostics promises to become a major activity. Agro-Bio and veterinary products amount to 23% of sales. The bulks are genetically- developed hybrid seeds for vegetable, crops, fruits and cotton, with resistance to pathogens, herbicide and adaptation to environments (Hazera, Zeraim Gedera, Rahan Meristem, Vitality). Poultry and farm animal vaccines (Abic), insects to fight plant Parasites (BioBee) and new cellulose- based technologies (CBD) contribute to Agro-Bio and 7
  8. 8. environmental control. Algae and fish cultures are other examples of the diverse food and bioneutraceutical sector. The Israeli Biotech sector is at a stage where it deserves energetic government support. It still needs more business managers, much more venture capital and infrastructures for advanced research, for clinical testing and registration, as well as for allowing young companies to develop their inventions into products. The Ministry of Industry and Trade has pledged to invest more of the R&D funds in Biotechnology. Its Office of the Chief Scientist has programs such as Magnet that allow a consortium of companies and Academic groups to develop novel generic technologies (A recent example is Daat for Bioinformatics and protein modeling). The Science Ministry has an infrastructure program, Tashtit. To expand scientific research on selected Biotech topics. A National Steering Committee advises the ministries on the choice of topics and has promoted the creation of National Centers for the most advanced Biotech technologies. These centers are infrastructures allowing scientists and industries to have access to equipment and methods that are essential for basic and applied Biotech projects. The existing centers are for: 1. Proteomics, including protein purification, microsequencing and mass spectroscopy 2. Transgenic animals and gene targeting (knock-outs) 3. Human genomic technologies, including large scale sequencing and mutation detection as well as DNA- arrays for simultaneous analysis of thousands gene profiles 4. Plant genome analysis and transgenic plants 5. Robotic high-throughput screening of molecular interactions 6. Bio- informatics, including computer networking for genome database mining, protein modeling and drug design With its strong potential, Biotechnology is the upcoming force in the high-tech industrial potential of Israel and, maybe more importantly, will make Israel a major contributor to the welfare of mankind, in terms of food and health. 8
  9. 9. Biotechnology in Israel: Securing a Prominent Place on World Markets During the last decade, Israel has emerged as a true world giant in such fields as software and communications. Similarly, this decade promises to be one in which Israel secures a prominent place in the arena of biotechnology, one in which Israel has already achieved many notable accomplishments. Analysts believe that biotechnology will be the next major growth area, surpassing the tremendous economic impact achieved by the advent of the personal computer, Internet communications and related fields. The hope and promise of Biotechnology is that its fruits will lead to improved health and longevity and that it will accomplish much of what medical science has yet to achieve, namely the eradication of many of the illnesses that still plague mankind. Biotechnology holds the promise not only to conquest many illnesses and genetic diseases, but also, through its agricultural applications, to contribute to the alleviation of the hunger and starvation that still afflicts much of the planet. Many of the factors responsible for the country’s prominent place in most of the dominant technologies of the past twenty years are also propelling Israel to center stage in the field of biotechnology. One of the contributing factors to this achievement is Israel’s high level of education and academic research. Israel boasts the world’s highest level of per capita spending on education and the highest numbers of physicians per capita as well. For example, 35% of its youth hold academic degrees from world-class universities in Israel and abroad. Israel has seven universities, each of whom boast international reputations in a number of fields. In addition, there are five technical colleges specializing in Life Sciences and ten research institutes heavily invested in R&D in biotechnology and related fields. Among the top research institutes are: 9
  10. 10. •1 Volcani Agricultural Research Center, part of the Hebrew University of Jerusalem •2 Technion’s Biotechnology Institute •3 Weizmann Institute of Science’s Depts. Of Molecular Genetics and Plant Genetics •4 The Center for Life Sciences, part of Tel Aviv University •5 The Institute for Applied Bioscience, part of Ben Gurion University of the Negev Each of these major universities has an R&D commercialization group whose aim is to find strategic partners in world markets for new products being developed in academia. Of particular importance to the field of biotechnology is the fact that 35% of all Israeli civilian research activities is in the area of life sciences. It is worth noting that from its beginnings in the early 1920s, Israel’s academic community has been characterized by a strong bent toward the life sciences. Israeli universities are renowned for their high profile life science research institutes, including a medical system actively involved in clinical investigation. Israeli researchers and academics publish their work in both Israeli journals and international publications. Almost 60% of academic publications are in bio and clinical medicine and related fields. Recent surveys by the distinguished British biomedical periodical, The Lancet, ranked Israel #1 in the world in per capita publication of technical and research papers. Historically, Israel has been at the front line of research in agro technology; it feeds its own people and exports its know-how throughout the world. Just as the defense industry, another historic technological pillar, provided much of the impetus for Israel’s success in electronics, so too agriculture, and in particular agro technology, has been one of the driving forces in the development of biotechnology. As a result, today, more than 40% of Israel’s biotech exports are in agricultural biotechnology. 10
  11. 11. At present, more than 160 commercial and related entities are engaged in biotechnology in Israel, with many products already being produced and marketed throughout the world while hundreds more are in the pipeline. Some of these companies have already become internationally known players in the field such as Biotechnology General, Hazera, Interpharm, XTL, Compugen, D-Pharm, Pharmos and Teva. The biotechnology sector currently employs more than four thousand people, the majority of whom have a college degree or higher. 2000 sales reached $800 million dollars and are expected to climb to $2 billion by 2003. 11
  12. 12. Biotechnology at Israel’s Universities Biotechnology requires rich academic soil in which to grow. More than any other high- tech industry, it must be nurtured carefully by the often long, arduous and expensive process of research. This characteristic makes Israel well placed to succeed in biotechnology with 35% of the country’s researchers involved in the life sciences. There have already been some remarkable commercial applications for Israeli biotechnology research, which is carried out at seven universities, five technical colleges and other research centers and hospitals. The Weizmann Institute of Science The Weizmann Institute of Science in Rehovot pioneered biotechnology in Israel and continues to do so today. InterPharm’s leading product, bulk recombinant human interferon-beta-1a for the treatment of multiple sclerosis, was developed at the Weizmann Institute’s Department of Molecular Genetics. InterPharm, owned by the Swiss-based corporation Serono, enjoyed sales of $50 million in 1999 and it is this kind of success that has persuaded many international companies to develop significant elements of their product in Israel. As a result of the Weizmann’s endeavors, the neighboring Kiryat Weizmann Science Park has become the national center of the country’s biotechnology industry with the largest companies based there. Today, the Weizmann Institute is contributing to the international Human Genome Project. One of the contributions of the Bioinformatics Unit in the Depart of Molecular Genetics is the study of mutated genes, which cause such disorders as Down’s syndrome and Alzheimer’s disease. Weizmann has its own technology transfer company – Yeda Research – and is also associated with the Pamot Venture Capital Fund, which holds right of first opportunity over any project under development by the Institute. Current biotechnology investments include 12
  13. 13. Gamida Cell, developing technologies for ex-vivo expansion and manipulation of stem cells in bone marrow and BALM Pharmaceuticals, developing a proprietary platform technology initializing diasteriomeric peptides. The Hebrew University of Jerusalem The Hebrew University of Jerusalem also allocates major resources to the life sciences. The university’s Biotechnology and Fermentation Laboratory is often held up as a model for a new generation of Precompetitive Industrial Research Centers (PRIC), in which industrial and academic scientists can work together on problems of scaleup and feasibility testing. Among successes in recent years, a team of HU researchers has created a new material – bioactive sol-gel glass – for immobilizing enzymes and other bioorganic molecules. The immobilized enzymes can even act as biosensors in medical or environmental applications. Another HU success is in the area of steroids. Researchers there have encapsulated steroids in microscopic vesicles where they are more accessible to chemical interactions. Yissum Technology is the Hebrew University’s technology transfer company. Once recent biotechnology commercial success in the area of bioinformatics based on HU know-how is Keryx. This Jerusalem start-up has developed a mathematical formula that harnesses raw genome data. The Technion Israel Institute of Technology The Technion in Haifa is also one of the country’s leaders in creating new industrial biotechnologies and moving them into industry. Among recent endeavors, a process has been developed for the elimination of toxic metal for drinking water and industrial effluents. The Technion R&D Foundation is responsible for technology transfer agreements at the university. One example of its success is Rademate Ltd., which is developing RBHM – a hydrophobic, strong, inexpensive and fully compost able, biodegradable composite material that is environmentally friendly. 13
  14. 14. Tel Aviv University Tel Aviv University’s Department of Microbiology and Biotechnology also conducts prolific research in these disciplines. Recombinant microbial biopolymers have been developed for treating oil pollution and metal contamination in natural water, while new classes of antibacterial and ant fungal drugs have been devised based on novel pathogen biochemistry. Another key link between the university and industry is exemplified by studies in bioprocessing in which enzymes are used for the controlled degradation of cellulose. In diagnostics research, cell-sorting technologies are used to enable rapid identification of human microbial pathogens. Tel Aviv’s technology transfer company is called Ramot. Ben Gurion University of the Negev One of Israel’s youngest biotechnology centers is in Beer Sheva at the Ben Gurion University of the Negev. The Institute of Applied Life Sciences (soon to become the National Research Center of Biotechnology) specializes in biomaterials, biosensors and bioenvironmental projects. Among projects sold to industry by the university’s technology transfer company – B.G. Negev Technologies and Applications – are a polysaccharide compound sold to Frutarom, a sugar compound acquired by global cosmetics firm Estee Lauder as an additive. Additionally, the university has developed a type of coral to be used as a bone substitute. The Migal Galilee Technology Center Located far to the north in Kiryat Shmona, this college has its own mini biotechnology incubator. Start-up companies include Galim, which has developed platform generic technologies for libraries of monoclonal antibodies, Sensis (together with Tel Aviv University), which is developing sequencers for DNA which are smaller, cheaper and more portable than existing devices, and Bioview, which is developing diagnostic equipment which uses image processing. In the past, Migal has developed recombinant vaccines for the treatment of Gambero disease in poultry, which is sold by Abic. 14
  15. 15. Bar-Ilan University and the Vulcani Center Among other projects, Bar-Ilan University researchers have developed a drug delivery system for Alzheimer’s disease. Another research institute is the Ministry of Agriculture’s Vulcani Center, an agricultural research organization near Tel Aviv. 15
  16. 16. A Comprehensive List of Israeli Biotechnology Companies Therapeutic Companies - Large Sized Companies - Biotechnology General Ltd. Contact Data Contact person: Dr. Dov Kanner, General Manager Address: Science Park, Kiryat Weizmann, Rehovot 76326 Tel: 972-8-9381122 Fax: 972-8-9409041 E -Mail: dovik@btgil.com Website: www.btgc.com General Information Year established: 1980 Number of Employees: 220 Annual Sales (1999) US$: 62.3M Core Business: Genetically engineered and other products for human healthcare. Areas of activity: Therapeutics: Ethical, Generic Platform Technologies: Genomics, Expression Systems Potential areas for collaboration: R&D Overview/Products Bio -Technology General develops, manufactures and distributes genetically engineered and other products for human health care: •1 Recombinant human therapeutics -Bio -Tropin, Delatestryl, Oxandrin OxSODrol, Arthrease, Imagex, Factorex. •2 Recombinant vaccines -Bio -Hep -B. •3 Viscoelastic devices for ophthalmology and orthopedics based on hyaluronic 16
  17. 17. acid -Biolon, BioHy. Expertise/Available R&D Capabilities •1 R&D objectives: Development of new proprietary pharmaceuticals for cancer therapy, immunotherapy and thrombolitic agents •2 R&D technology: Production of recombinant human molecules for human health care •3 R&D applications: Gene cloning, Synthetic DNA and Gene assembly. Expression of recombinant proteins in E-coli, yeast and mammalian cells. Biological assessment (animal models). Clinical trials. Sci. discipline: Cardiovascular, endocrinology and cancer therapy InterPharm Laboratories Ltd. Contact Data Contact person: Dr. Ezra Ouziel, General Manager Address: Science-Based Industrial Park, Kiryat Weizmann, Rehovot 76110 Tel: 972-8-9382424 Fax: 972-8-9407566 E -Mail: hr.interpharm@serono.com General Information Year established: 1978 Number of Employees: 250 Annual Sales (1999): US$49.7M Core Business: Biological pharmaceuticals. Production of cytokines. Areas of activity: Therapeutics, Ethical Overview/ Products InterPharm is a subsidiary of Ares- Serono, dedicated to research, development and production of bulk biological pharmaceuticals. The lead product is recombinant interferon - beta, marketed by Ares -Serono as Rebif (r) for multiple sclerosis patients. Expertise/Available R&D Capabilities Recombinant production of proteins 17
  18. 18. OMRIX Biopharmaceuticals Ltd. Contact Data Contact Person: Moshe Baru, R&D Manager Address: Weizmann Science Park, Bldg 14, Ness-Ziona P.O.Box: 619 Rehovot 76106 Tel: 972-8-9001480 Fax: 972-8-9001219 E-Mail: israel@omrix.co.il Website: www.omrix.com General Information Year established: 1995 Number of Employees: 150 Annual Sales (1999): U.S. $18M Core Business: Formulation of proteins with liposomes to improve the pharmacokinetics, stability and toxicity of the proteins and Gene Therapy by liposome-encapsulated DNA Areas of activity: Therapeutics, Ethical, Human plasma products Potential areas for collaboration: Investments, R&D, Marketing Overview/Products OMRIX currently offers three product groups: 1. Surgical sealants: Representing a new class of tissue sealants, QuixilT provides the surgeon with a new tool for wound closure in addition to sutures, staples and diathermy. 2. Immunoglobulins: Omr-IgG-am polyvalent immunoglobulins for IV or IM use, hyperimmune Anti D immunoglobulin and hyperimmune Anti Hepatitis B IV immunoglobulin for the treatment or prevention of immunological disorders. 3. Traditional plasma derivatives: Such as Human Albumin for plasma volume replacement and coagulation factors (Factors VIII and IX) for the treatment of haemophilia patients. 18
  19. 19. International Headquarters Address: 200 Chaussée de Waterloo, B-1640 Rhode-St.-Genèse, Belgium Tel: +32-2-359 9123 Fax: +32-2-359 9149 Orgenics Ltd Contact Data Contact person: Dr. Ouriel Faktor, R&D Manager Address: P.O.Box: 360, Yavne, Israel, 81103 Telephone: 972-8-9429201 Fax: 972-8-9438758 Email: info@orgenics.co.il Website: www.orgenics.com General Information Established: 1982 Ownership: Private Parent: Selfcare Employees: 100 Core business: Diagnostics, simplified format for sophisticated biotechnology. AIDS test- DNA probe. Turnover (1997): US $12,15 M Market regions: France, Brazil, Argentina, Philippines, Germany Main Markets: Government institutions, hospitals, clinics, army Overview/Products Orgenics Ltd. develops, manufactures and markets sophisticated, yet user friendly, self- contained In-Vitro diagnostic kits. The company's line includes a comprehensive line of tests for AIDS, Hepatitis, Chlamydia, TORCH and H. pylori. The tests excel in their user- friendliness and cost efficiency, including either visual interpretation or CombScan II-A computerized linked reader. The line includes ImmunoComb II-A series of 25 self contained in-vitro diagnostic EIA tests: DoubleCheckHIV 1&2 - 10 minutes screening and 19
  20. 20. resolution of suspected negative HIV patients; GeneComb - integrates immunoassay format with DNA probing technology, and allows most sensitive simultaneous detection of several disease merkets in 30 minutes. Meeting stringent performance/containment demands, Orgenics' HIV system is used by the World Health Organization for its global campaign against AIDS. Teva Pharmaceutical Industries Contact Data Contact Person: Ms. Dorit Meltzer, Investment Relations Manager Address: 5 Basel St. Petach Tikva, 49131 Tel: 972-3-9267267 Fax: 972-3-9234050 E-Mail: in@teva.co.il Website: www.tevapharm.com General Information Year established: 1930 Number of Employees: 6,000 Annual Sales (1998): U.S. $ 1.12B Core Business: Generic, Branded and Innovative drugs, Active Pharmaceutical Ingredients, Hospital Supplies and Veterinary Products. Areas of activity: Therapeutics, Ethical, Generic, AgBio, Veterinary Potential areas for collaboration: Investments, R&D, Marketing Overview/Products Teva Pharmaceutical Industries is a global company with headquarters in Israel. The company develops, manufactures human pharmaceuticals, bulk pharmaceutical chemicals, medical disposables, veterinary products and fermentation products. Teva is also targeting the ethical drug market with its Copaxone, a multiple sclerosis drug which recently received FDA approval as a therapy for the treatment of patients with relapsing remitting multiple sclerosis. 20
  21. 21. - Medium-Sized Companies - D-Pharm Ltd. Contact Data Contact person: Dr. Yaffa Beck, Executive VP and COO Address: Kiryat Weizmann, Science Park Bldg.16-18, P.O.Box 2313, Rehovot 76123 Tel: 972-8-9300794 Fax: 972-8-9300795 E-Mail: info@dpharm.com Website: www.dpharm.com General Information Year established: 1993 Number of Employees: 77 Core Business: Novel technologies for targeted drug delivery Areas of activity: Therapeutics, Ethical, Platform Technologies, Drug targeting Potential areas for collaboration: R&D, Licensing Overview/Products D -Pharm has developed a unique and synergistic set of Selective Molecular Activation and Routing technologies (D -SMARt tm) that capitalize on the body's stress response mechanisms and molecular trafficking systems to enable disease specific drug targeting and activation. Two of D-Pharm's products, namely, DP-VPA, for the treatment of epilepsy, and DP-b99, for the treatment of acute stroke are about to commence phase II by the end of this year. Other programs for inflammation, neurodegeneration, AIDS and cancer are at various stages of development. Expertise/Available R&D Capabilities D-Pharm is focusing its product development efforts on the central nervous system and cerebro-vascular disorders. D-Pharm is also developing products for Cancer and AIDS. 21
  22. 22. International Headquarters Address: D-PHARM US Inc. 207 Commons Way, Chapel Hill, NC 27516, USA Tel: 1- 919-928-0772 Fax: 1-919-928-0771 Email: dpharmus@earthlink.net Healthcare Technologies Ltd Contact Data Contact person: Mr. Daniel Kropf, Chairman and CEO Address: 3 Habosem St. Ashdod, Israel, 77610 Telephone: 972-8-8562920 Fax: 972-8-8563258 Email: contact@hctech.com Website: www.hctech.com General Information Established: 1988 Type: Holding company Parent: Gamida For Life group, the Netherlands. Core business: Development, registration, manufacture and marketing of clinical diagnostic test kits. Overview/Products Healthcare Technologies Ltd, established in 1988 is an Israeli company quoted in New- York (NASDAQ-HCTLF). The company, through its subsidiaries and affiliates and a worldwide network of distributors, specializes in the development, registration, manufacture and marketing of clinical diagnostic test kits. The company, is committed to supplying its customers throughout the world with products of high quality, supported by intensive research and development programs, rigorous quality control procedures, and dedicated technical and customer service teams. The company's major shareholder is the Netherlands-based Gamida for life group, which is itself engaged internationally in the research, development, production and sale of products 22
  23. 23. and services for healthcare through its subsidiaries and other associates. Healthcare Technologies Ltd. provides: • Diagnostic, Research/QC tools, to laboratory professionals in Israel • Diagnostic tools to professionals in Laboratory and in POC worldwide • OTC - for infectious diseases • Manufacturing and developing services to third parties. So that they can diagnose their patients accurately, widen their understanding of health and disease. Kamada Ltd. Contact Data Contact person: Mr. David Tsur, Managing Director Address: Kiryat Weizmann, Rehovot 76327 Tel: 972-8-9406472 Fax: 972-8-9406473 E -Mail: kamadeal@kamada.com Website: www.kamada.com General Information Year established: 1990 Number of Employees: 75 Annual Sales (1999): US$ 14M Core Business: Development and manufacturing of pharmaceuticals, including: injectables, parenteral solutions blood derivatives and raw materials for the pharmaceutical industry. Areas of activity: Therapeutics, Plasma products Overview/Products Kamada Ltd. is a pharmaceutical company specializing in the production of the high quality injectables by large-scale chromatographic purification methods. The main products of Kamada include: injectables, parenteral solutions, blood derivatives and raw materials for the pharmaceutical industry. All products meet the requirements set by the British and/or United States Pharmacopeia. Kamada's products include: 23
  24. 24. • Pharmaceuticals: Human Albumin 20% & 25%, Protosol (aprotinin), Heparin Sodium, Heparin Lock Flush, Protamine Sulfate, Dopamine Hydrochloride, Electrolyte Solutions and Immunoglobulins. • Raw materials: Chymotrypsin, Trypsin, Aprotinin, Superoxide Dimutase, H. Transferrin, Deoxyribonuclease I, Ribonuclease, Heparanase. Expertise/Available R&D Facilities Kamada maintains a complete line of equipment for chromatographic purification of therapeutic proteins. Novamed Ltd Contact Data Contact person: Dr. Emil Katz, President & CEO Address: 28 Pierre Koenig St. P.O.Box: 53231 Jerusalem, Israel, 91531 Telephone: 02-6781861 Fax: 02-6781852 Email: info@novamed.co.il Website: www.novamed.co.il General Information Established: 1995 Core business: Products for research labs and clinical diagnostics centers. Employees: 35 Turnover (2001): U.S. $2,5 M Market regions: France, Italy, Japan, USA Main Markets: Clinical laboratories Overview/Products Novamed Ltd. is a privately owned Israeli life science company founded in December 1995. Since its inception Novamed has been committed to the development of innovative, proprietary diagnostic systems with worldwide marketing potential. Novamed has become an important player in selected markets by combining user need for a particular application with a cost-effective product. Such products include the patented and FDA approved DipStreak and ChromoStreak devices for diagnosis of urinary tract infections and 24
  25. 25. NovaStreak for detection of microorganisms present in food and dairy products. Novamed's rapid one-step diagnostic assays for viral infections (AdenoStick, RotaStick and CombiStick) are all the latest third generation products. Novamed's Uni-Sep and Uni-Sorb line of products have modernized procedures for lymphocyte isolation and separation. All Novamed's products are performance tested in a stringent quality control program, according to ISO-9002 standards. Novamed's unique corporate structure enables the company to be both well established with a proven record of success in production, sales and support, while allowing it to be an aggressive "start-up" in regards to development of new products and methodologies. Peptor Ltd. Contact Data Contact person: Yoram Karmon, President, CEO & Director Address: Kiryat Weizmann, POB 43, Rehovot 76326 Tel: 972-8-9387777/04 Fax: 972-8-9407737 E -Mail: yoram@peptor.co.il Website: www.peptor.co.il General Information Year established: 1993 Number of Employees: 53 Core Business: Peptor Ltd. specializes in the optimization and manufacturing of drugs based on Small Cyclic Analogs of Peptide Loops. Areas of activity: Therapeutics, Ethical, Platform Technologies Potential areas for collaboration: R&D, Marketing Overview/Products The company uses combinatorial chemistry to generate analogs of the peptide loops that are found in the active parts of large proteins and peptides. Peptor's initial efforts are concentrated on therapeutic drugs, particularly those targeting autoimmune disorders, infectious diseases and cancers. Peptor's competitive edge is based on a proprietary technology platform, which enables the manipulation of a key player in the immune system 25
  26. 26. -Heat Shock Protein 60. The drugs being developed by the company consist of SCAPLs, which switch off various immune system patterns associated with hsp60. Peptor's first drug, DiaPep277 is a treatment for Type 1 Diabetes. It is designed to prevent the deterioration of insulin producing beta cells. Expertise/Available R&D Facilities R&D markets: Drug Screening, Molecular Biology and Biochemistry of Hormone Receptors and Peptide Chemistry. International Headquarters Address: Peptor GmbH - Max-Planck-Strasse 15b 40699 Erkrath, Germany Tel: +49 (0) 211 291949 0 Fax: +49 (0) 211 291949 29 Email: info@peptor.de ProChon Biotech Ltd. Contact Data Contact person: Dr. David Aviezer, General Manager Address: Kiryat Weizmann, Science Park, Bld. 12, POB 1482 Rehovot 76114 Tel: 972-8-9401570 Fax: 972-8-9401813 E-Mail: aviezer@prochon.co.il Website: www.prochon.co.il General Information Year established: 1997 Number of Employees: 30 Core Business: Research and Development of treatments for skeletal disorders and other bone and cartilage diseases Areas of Activity: Therapeutics, Ethical, Platform Technologies, Tissue Engineering Cell Therapy Potential areas for collaboration: R&D, Marketing, Investment 26
  27. 27. Overview/Products Prochon is devoted to the discovery, development and commercialization of novel therapeutic approaches for the treatment of genetic and acquired skeletal disorders. These include: short-limbed dwarfism, benign and malignant tumours of bone and cartilage, inflammatory joint disorders, bone fracture healing and cartilage repair, based on its strong molecular biology platform, proprietary growth factors and tissue engineering related technology. In addition, Prochon is vigorously exploring the use of its FGF technology for the development of treatments to enhance fracture healing and regenerate damaged cartilage or post traumatic and osteoarthritic joints. Prochon has developed through its subsidiary company, CTI-Cell Transplantation Innovations Ltd., a capacity to propagate human cartilage derived cells as a basis for new generation therapies based on chondrocyte transplantation. Prochon's autologous chondrocyte transplantation procedure, Bio Cart, has been approved by the Israeli Ministry of Health for treating patients suffering from traumatic and other cartilage lesions in the knee. Proneuron Biotechnologies (Israel) Ltd. Contact Info Contact person: Mr. Nir Nimrodi, CEO Address: P.O.B. 277 Ness Ziona 74101 Tel: 972-8-9409550 Fax: 972-8-9409560 E -Mail: info@proneuron.com Website: www.proneuron.com General Information Year established: 1996 Number of Employees: 23 Core Business: Cell therapies and other treatment strategies for neurological, ophthalmologic and immune-related disorders Areas of activity: Cell Therapy Potential areas for collaboration: Investment, R&D 27
  28. 28. Overview/Products The company develops technologies for the treatment of disorders of the human central nervous system (CNS) by modulating the immune response occurring in the CNS. The goal of the Company is to develop therapies to induce CNS regeneration and neuroprotection. Proneuron develops therapies for neurological, ophthalmologic and immune -related disorders: • Autologous Macrophages -for the regeneration of CNS neurons damaged by physical trauma, such as spinal cord injury. • Autologous T-Lymphocytes -for protecting neuronal cells against death resulting from ischemia, trauma or chronic diseases such as Alzheimer's and Parkinson's. • Immune Privilege Factor (IPF) -an anti-inflammatory compound potentially useful for treating ophthalmic and degenerative CNS diseases, as well as other non-CNS immune -related disorders. XTL Biopharmaceuticals Ltd. Contact Data Contact person: Dr. Martin Becker, President Address: Kiryat Weizmann Bldg. 3, POB 370 Rehovot 76103 Tel: 972-8-9405134 Fax: 972-8-9405017 E -Mail: info@xtlbio.com Website: www.xtlbio.com General Information Year established: 1993 Number of Employees: 65 Core Business: Novel chimeric pharmaceuticals based on human monoclonal antibodies. Areas of activity: Therapeutics, Ethical, Platform Technologies Overview/Products XTL Biopharmaceutical Ltd. is focused on developing therapeutics to treat hepatitis B and C and other infectious diseases utilizing its proprietary drug discovery and development "engine", the Trimera XTL System. This technology integrates two critical aspects of the 28
  29. 29. drug discovery process; Generation of therapeutic leads (in the form of fully human monoclonal antibodies) and in vivo preclinical lead validation in sophisticated human disease models resulting in condensed development timelines with lowered clinical risks. The multifaceted nature of the Trimera XTL System enables a diversified business strategy with both a product and toolbox focus. Zer Hitech (1976) Ltd. Contact Data Contact person: Mr. Uri Zer, General Manager Address: 3 Shatner Center, Givat Shaul B, Jerusalem, Israel, 95461 Telephone: 972-2-6522462 Fax: 972-2-6512898 Email: azer@zerhitech.com General Information Established: 1976 Ownership: Private Employees: 60 Core business: In-vitro and one -step diagnostics kits. Market regions: Europe, Far East, South America Overview/Products The Zer Group, a leading biotechnology company, was founded in 1976 by Dr. Avraham Zer and Dr. Tami Zer. ZER concentrates on fertility related and infectious disease products - research, development and manufacture of Diagnostic assays (ZER HITECH), and also has a network of medical service laboratories servicing hospitals, private laboratories and medical institutions in Israel (Zer Laboratories). The companies comprising the Zer Group, although separate and independent entities, work closely together to provide complementary services and products through close-knit cooperation on quality control, clinical testing and information feedback. Zer Hitech (1976) Ltd. develops, manufactures and markets One-step assays: • Pregnancy tests, Dipstrip, Card and Midstream format. • LH-Ovulation tests, Card and Midstream formats 29
  30. 30. • FSH-Menopause tests, Card and Midstream formats • Amniotest • Monoline pregnancy test In addition, ZER has developed and manufactures Innovative HIV 1+ 2 for Whole Blood, Saliva, Serum and Plasma, as well as Hepatitis B; Drugs of abuse; Chlamydia; Strep A and B; H. pylori; Occult blood and other assays. - Small-Sized Companies - BALM Pharmaceuticals Ltd. Contact Data Contact Person: Dr. Nurit Eyal, CEO Address: Kirtat Atidim, Bldg 4, POB 58078 Tel Aviv, 61580 Tel: 972-3-6448808 Fax: 972-3-6448804 E-Mail: neyal@pamot.com General Info Year Established: 1997 Core Business: Use of diastereomer peptides to develop antibacterial, antiviral, anti- fungal and anti cancer compounds. Areas of Activity: Therapeutics, Platform Technology Potential areas for collaboration: R&D in these areas: • Development and improvement of antibiotics for human applications. • Development of anti cancer drugs. • Development of anti-fungal and antibacterial components for agriculture applications, including seed treatment and crop dusting components. • Development of antibacterial compounds for fishponds treatment. • Development of anti-infecting materials for food preservation. • Development of anti-mycoplasma and antibacterial peptides for treatment of growth mediums, such as tissue culture, for the research and the pharmaceutical market. 30
  31. 31. Overview/Products Balm Pharmaceuticals Ltd. is utilizing its "Smart Screening" technology to develop diastereomeric peptides as novel anti-cancer and anti-microbial selective compounds. The diastereomers can be used as an antibacterial, anti-fungal, anti-viral and anti-tumor agent. Preliminary results indicate specific activity of different diastereomers against bacteria and cancer. These results can lead to the development of a new type of antibiotic components that would have substantial advantage over current available antibiotics. Cytolab Ltd. Contact Data Contact person: Zippora Stabinsky, General Manager Address: Tamar Building, Rabin Park, 12 Hamada St., Rehovot 76703 Tel: 972-8-9460948 Fax: 972-8-9460861 E -Mail: cytolab@netvision.net.il Website: www.peprotech.com General Information Year established: 1991 Number of Employees: 4 Core Business: Cytokines, growth factors and antibodies. Areas of activity: Therapeutics – Generic, Services Contract Research and Manufacturing Potential areas for collaboration: R&D, Marketing Overview/Products CytoLab is a biotechnology company fully dedicated to the mission of supplying the scientific community with a complete line of top quality cytokine products and their related antibodies. The company develops an extensive line of recombinant human, murine and rat cytokines, production and marketing cytokines, growth factors and antibodies from milligram to gram quantities. 31
  32. 32. Ester Neurosciences Ltd. Contact Data Contact person: Dr. Oded Ben-Joseph, General Manager Address: 2 Koifman Street, Textile House, 16th floor, Tel Aviv 68012 Tel: 972-3-5160577 Fax: 972-3-5160576 E-Mail: info@esterneuro.com Website: www.esterneuro.com General Information Year established: 1997 Core business: Novel compounds for myasthenia gravis and other peripheral Nervous system disorders. High throughput, screen for identification of drug candidates for cholinergic disorders of the central nervous systems. Areas of activity: Therapeutics - Ethical Potential areas for collaboration: Investment, R&D Overview/Products Ester is a development stage biopharmaceutical company committed to the discovery and development of novel therapeutic products for the treatment of neurological disorders such as myasthenia gravis, Alzheimer's and Parkinson's diseases, multiple sclerosis and others. Ester’s unique platform technology is based on the company's breakthrough discoveries relating to cholinergic neuromodulation and its involvement in the diseased state. Neural Stress Response (NSR) is a concept developed by Ester based on its discoveries, which provides a novel paradigm for drug discovery and therapeutics of neurological disorders. Ester's NSR concept also predicts, explains and offers solutions to the limitations inherent in currently marketed drugs for neural stress-related disorders. Ester has developed an antisense product AS3, to prevent the biosynthesis, as opposed to inhibiting the enzymatic activity, of AchE protein in brain cells and tissues. This is the only means known to eliminate both the enzymatic and neuronal deterioration functions of AchE, in addition, strategies are being pursued to develop screening assays for small molecule inhibitors to black the non enzymatic activity of AchE. 32
  33. 33. Genena Contact Data Contact person: Dr. Ben-Tzion Wider, Manager Address: 7 Haofe St., Ashkelon Technological Industries - Tech. Incubator, P.O.Box: 7284 Ashkelon, Israel, 78172 Telephone: 972-8-6711852 Fax: 972-8-6711855 Email: ati@ati.co.il General Information Established: 2002 Parent: Ashkelon Technological Industries - ATI Core business: Laboratory kit for measuring genetic expression Overview/Products The kit determines the extent of expression of families of genes (on the level of mRNA). The testing kit is integrated with a statistical program that allows for unique analysis of the genetic components of a cell and their comparison to other cells. The whole kit represents a particular family of genes, and contains test tubes, each of which has a combination of a pair of primaries suitable for particular areas reserved by the family of genes. The quantity of primaries in the kit enables repetition of the tests in 40 different conditions. The developed kits are principally suited for scientific use, in clinical and scientific research in fields such as molecular biology, genetic engineering and drug development - gene therapy. Every scientist interested in the determination of genotype of cells, whether `engineer' or an examiner of various materials on the genes, may utilize these kits. These kits supply differential information, and are easy to use. They do not require additional equipment, apart from the PCR item. The suitable market consists of agricultural researchers, researchers in clinical laboratories, various diagnostic laboratories including quality testing and toxicology, and thus pharmaceutical companies involved in development. The novelty lies in the focus of the work, on the framework of particular gene families and 33
  34. 34. the use of primaries from reserved areas of such genes to determine the level of expression of the genes. In a few reactions it is possible to cover a pattern of expression of a whole family of genes, to receive a realistic picture relating to all genes pertaining to the family that is expressed in the tissue, and thus work on organisms whose genotype is not determined. Genzyme Israel Ltd Contact Data Contact person: Mr. Zeev Zelig, General Manager Address: 20 Hataas St., Beit Hapaamon, P.O.Box: 1188, Kfar Saba, Israel, 44111 Telephone: 972-9-7666640 Fax: 972-9-7666631 Email: zelig@genzyme.co.il Website: www.genzyme.com General Information Type: Affiliate of foreign Corporation Core business: Development of patented drugs for rare hereditary diseases and of a new generation of cancer drugs. Overview/Products Genzyme Israel Ltd. is a division of a worldwide corporation, a biotechnology company that develops and markets innovative products and services for unmet medical needs. With three divisions, each targeting a specific area of expertise, Genzyme Corporation combines the resources and strengths of one of the world's largest biotechnology companies with the entrepreneurial spirit and dedication of focused, flexible, and independent businesses. Genzyme uses a wide range of technologies in its research and development efforts. With a strong international infrastructure, including extensive capabilities in sales and marketing, manufacturing, and regulatory affairs, Genzyme has a successful track record in working closely with patients and physicians. The company has three divisions. Genzyme Corporation has issued a separate series of common stock that is designed to reflect the value of each division. 34
  35. 35. • Genzyme Biosurgery - is bringing biotechnology to surgery through a unique combination of biotherapeutics, advanced biomaterials and sophisticated devices. Focused on the areas of orthopaedic and cardiothoracic surgery, the division is defining and leading the new field of biosurgery, which has the potential to achieve revolutionary improvements in patient care. • Genzyme General - develops and markets therapeutic products and diagnostic products and services. The division has four therapeutic products on the market and a strong pipeline of therapeutic products in development focused on the treatment of genetic disorders and other chronic debilitating diseases. Genzyme General also manufactures and markets diagnostic products, genetic testing services, and pharmaceutical intermediates. • Genzyme Molecular Oncology - is developing a new generation of cancer products, focusing on cancer vaccines and angiogenesis inhibitors. This division of Genzyme is shaping these new therapies through the integration of its gene discovery, gene therapy, small molecule drug discovery, protein therapeutic, and genetic diagnostic efforts. Green Care Laboratories Ltd. Contact Data: Contact person: Mr Eli Gimmon, CEO Address: 10 Zarhin Street, POB 3030, Raanana, Israel, 43662 Tel: 972-7-6602888 Fax: 972-7-6602777 E -Mail: egimmon@megiddo.co.il General Information: Year established: 1996 Number of Employees: 10 Core Business: Platform technologies in Biotechnology, bioinformatics, generic therapeutics, plant AgBio. Areas of activity: Therapeutics – Generic, AgBio – Plant, Platform Technologies, 35
  36. 36. Bioinformatics. Potential areas for collaboration: Investments, R&D Overview/Products Green Care Laboratories Ltd. is a start-up company specializing in the development of enzymatic inhibitors for fighting infectious diseases in plants and humans by using computer assisted drug design. The company creates biodegradable fungicides that are non-toxic for mammals: "drugs for plants". The targets for these drugs are enzymes that do not exist in plants and mammals, and are crucial for the synthesis of pest's tissues only. The main products are agricultural Pesticides, Medical Drugs, ADEIN Advanced Database for Enzymatic Inhibitors. Lipogen Products (9000) Ltd. Contact Data Contact person: Mr David Rutenberg, General Manager Address: 60 Harofeh St. P.O.B 7687, Haifa 31078 Tel: 972-4-8255217 / 972-52-522355 / 972-4-9990011 Fax: 972-4-8342527 E -Mail: lipogen@compuserve.com Website: www.lipogen.co.il General Information: Year established: 1990 Number of Employees: 10 Core business: A unique process for the production of phosphatidylserine (PS) from the soy lecithin. The complex is used for controlling Dementia and Alzheimer disease. Areas of activity: Therapeutics – Ethical, AgBio - Food Potential areas for collaboration: Marketing Overview/Products Since 1992 Lipogen Ltd. in Israel was the first to introduce soy lecithin PS. The enzymatic reaction process for the production of Lipogen PS utilizes cabbage enzyme instead of the optional bacterial enzyme. The Lipogen PS is the first natural process for "clean", 100% 36
  37. 37. solvent free phosphatidylserine (PS) and phosphatidic acid (PA). The Lipogen phosphatidylserine preparation has been twice clinically tested in a double blind placebo controlled studies. Currently this is the only soy derived phosphatidylserine complex, which has been so far tested. Taking into consideration the remarkable clinical results of the Lipogen phospholipids formulation and the facts that its components naturally reside in our body provide an attractive novel product for physicians to consider. Mindsense Biosystems Ltd Contact Data Contact person: Mr. Nir Nimrodi, General Manager Address: 12 Hamada St., Tamar Building, Entrance A, Rabin Park Rehovot, Israel, 76703 Telephone: 972-8-9316664 Fax: 972-8-9316665 Email: ayelet@mindsense.com Website: www.mindsense.com General Information Established: 1996 Ownership: Private Employees: 16 Turnover (2000): US$ 7,1 M Core business: Biochemical Diagnostic and Monitoring tools for neuropsychiatric disorders. Overview/Products Mindsense Biosystems Ltd. is committed to the research, development and marketing of a variety of products, which are based on the understanding of the biological mechanisms of mental disorders. Mindsense is currently developing the first biochemical blood test for the diagnosis and monitoring of mental disorders. The breakthrough, proprietary technology of the company is based on the discovery that certain G-proteins (a prominent component in cellular signal transduction) undergo quantitative and functional state-dependent modifications during typical episodes 37
  38. 38. of mental and certain CNS diseases. These illnesses include depression, Mania, schizophrenia and panic disorders and Parkinson's disease. The Mindsense technology will significantly improve the administration of a timely treatment to the patients, their quality of life and add greater economic value to the medical community. Mindset Biopharmeceuticals Ltd. Contact Data Contact person: Dr Daniel Chain, President & CEO Address: 5 Hamada Street, Har hozvim, P.O.B. 45032, Jerusalem 91450 Tel: 972-2-5412727 Fax: 972-2-5412726 E -Mail: dchaim@mindset.co.il Website: www.mindset.co.il General information Year established: 1997 Number of Employees: 4 Core business: Biotechnological and pharmaceutical methods for the prevention and treatment of brain disorders. Areas of activity: Therapeutics – Ethical, Platform Technologies - Gene Therapy Potential areas for collaboration: R&D Overview/Products Mindset develops ethical drugs for the treatment of Alzheimer's disease and other neurological disorders and methods to assist in the design of small drug molecules. Mindset has two major therapeutic programs in Alzheimer's disease: a unique small molecule pharmacological approach aimed at reducing amyloid burden and oxidative stress in the brain; and an immunotherapeutic program to immunize and treat patients. The company has also developed a highly specialized platform for drug discovery in transgenic models. Mindset Biopharmaceuticals Ltd. is a subsidiary of a USA registered company. All the company's research and development related activities are managed by its Israeli subsidiary. 38
  39. 39. Modus Biological Membranes Ltd. Contact data Contact person: Mr. Baruch Bahat, General Manager Address: 16 Hess St., Rehovot, Israel, 76346 Tel: 972-8-9462636 Fax: 972-8-9365326 E-Mail: shenfeld@zahav.net General Information: Year established: 1996 Number of Employees: 7 Core business: Pharmaceutical products for alleviation of withdrawal symptoms Areas of activity: Therapeutics - Ethical Potential areas for collaboration: Investment, Marketing Overview/Products Modus Biological Membranes Ltd. (Modus) develops and designs novel, naturally derived, patentable pharmaceuticals that greatly reduce or eliminate withdrawal symptoms in multi- billion dollar market segments. Modus' first patented formulation, LibertalT, is based on 15 years of advanced cell membrane research. To capitalize on its breakthrough formulation, the Company is initially targeting the lucrative smoking cessation and menopause hot flush syndrome markets. Initial discussions are underway with leading pharmaceutical firms regarding strategic partnerships. FDA and EC-approved smoking and menopause products are expected to be launched internationally in 2004. In parallel, Modus is developing LibertalT product lines to treat alcohol, ethical drug and street drug withdrawal symptoms. FDA and EC- regulatory approved products are slated to be launched worldwide in 2004 and 2005, respectively. The Company's marketing strategy and initial target markets were chosen based on consultations with one of the world leaders in pharmaceutical market research, PriceWaterHouse Cooper (Coopers & Lybrand). The company received 3 PCT patents that cover it scientific developments. 39
  40. 40. Natural Compounds Contact data Contact person: Dr. Nitsa Mirsky, General Manager Address: Beit Mitzpor, Oranim, Tivon Israel, 36006 Tel: 972-4-9532654 / 9838725 Fax: 04-9930170 E -Mail: nmirsky@bezeqint.net General Information Year established: 1994 Number of Employees: 6 Core Business: Extraction and purification of anti diabetic and anti CVD products derived from natural sources. Areas of activity: Therapeutics - Ethical Potential areas for collaboration: Investments, R&D, Marketing Overview/Products Natural Compounds is a privately owned young company, specializing in the development of innovative new line of oral anti-diabetic and anti lipidemic compounds derived from natural sources - yeast cells and a plant. The company has successfully conducted an extensive series of in vitro and pre-clinical experiments of its products, demonstrating high and immediate hypoglycemic and hypolipidemic effects on both types of diabetes. Oral administration of a single dose of the anti diabetic compounds to diabetic animals remarkably decreases glucose and lipids levels in their blood. The products also reduce the level of lipid peroxides in blood and tissues, decreasing atherosclerosis processes. The products, which possess high and rapid anti diabetic activity and a favorable safety profile, may fill a major gap in the area of anti diabetes therapy. Additional products in the company's pipeline are anti-cataract, Aldose reductase inhibitor and antioxidants. 40
  41. 41. Neurim Pharmeceuticals (1991) Ltd Contact Data Contact person: Prof. Nava Zisapel, Executive Managing Director Address: 8 Hanechoshet St. Tel Aviv, Israel, 69710 Telephone: 972-3-6499340 Fax: 972-3-6494568 Email: neurim@netvision.net.il General Information Established: 1991 Ownership: Private Parent: Zisapel family Employees: 17 Core business: Pharmaceutical and Biomedical industry Overview/Products Neurim Pharmaceuticals (1991) Ltd. is a biomedical and pharmaceutical technology development company. Neurim's mission is to create new, innovative, safe, and effective therapeutics, which satisfy unmet medical needs associated with advanced age. Neurim has submitted a full Marketing Authorization Application for Circadin 2mg (prolonged-release melatonin) in Europe, Canada, and Switzerland). Within the next two years Neurim expects to establish a therapeutic leadership position of Circadin 2mg in age related chronic insomnia as well as to further expand into two new clinical indications. Three additional, novel, patents protected, break-through pipeline products will enter accelerated product development programs with the objective to bring to market 2 additional proprietary therapeutics within the next 5 years. Neurosurvival Technologies Ltd Contact Data Contact person: Dr. Ilan Ziv, CEO Address: 11 Haodem St. P.O.Box: 7119 Petach Tikva, Israel, 49170 Telephone: 972-3-9215716 41
  42. 42. Fax: 972-3-9215714 Email: nst@nst.co.il Website: www.cii.co.il General Information Established: 1996 Ownership: Private Employees: 15 Core business: Biopharmaceutical company. NeuroSurvival Technologies for Effective Neuroprotection Overview/Products Neurosurvival Technologies Ltd. (NST) - is a biopharmaceutical company established in 1996, that focuses on developing innovative products, diagnostics, and therapies for the detection, delay and intervention in Apoptosis processes (programmed cell death). Apoptosis is a gene-based self-destructive program that exists in every cell of the human body. The discovery of this "suicidal" cellular activity constitutes a major scientific advancement. Interference in the Apoptosis suicidal process represents a major breakthrough in the inhibition of numerous Central Nervous System degenerative disorders, such as Parkinson's, Alzheimer's, and various cancers. OMRI Laboratories Ltd. Contact Data Contact: Name: Dr. Moshe Baru, R&D Manager Address: Weizmann Science Park, Bld. 14, P.O.Box: 619, Rehovot, Israel, 76106 Telephone: 972-8-9301480 Fax: 972-8-9301219 Email: israel@omrix.co.il Website: www.arrowecology.com General Information Year established: 1992 Number of Employees: 4 42
  43. 43. Core business: Ethical therapeutics - Encapsulation of macromolecules in liposomes for sustained release of sensitive proteins; Gene therapy by liposome-encapsulated DNA. Areas of activity: Therapeutics - Ethical Potential areas for collaboration: Investment, R&D. Overview/Products The mission of OMRI Laboratories is to develop and commercialize medically novel, innovative therapeutics covering wide indications and large markets. Presently, OMRI is developing proprietary technologies, which include: • Formulations of factor VIII with liposomes to improve the pharmacokinetics and stability of the factor. • Formulation of proteins with liposomes to improve the pharmacokinetics, stability and toxicity of the proteins. • Gene therapy by liposome-encapsulated DNA: a) Gene therapy of lung and liver cancer; b) Gene transfer into the liver following operative procedures and induction of tolerance to liver allograft by liposome mediated gene transfer; c) Production of antibodies following gene transfer by liposome-encapsulated DNA. Polyheal Ltd. Contact Data Contact person: Dr. Menahem Zeevi, CEO Address: 44 Bar-Yehuda St., Nesher, 20300, P.O.Box: 25205, Haifa, Israel, 31250 Telephone: 972-4-8207917 Fax: 972-4-8207919 Email: polyheal@polyheal.co.il General Information Year establishes: 1996 Number of Employees: 5 Core business: Microspheres for medicine; Treatment for wound healing. Areas of activity: Therapeutics 43
  44. 44. Overview/Products Polyheal Ltd. is a start-up R&D company. The company received a US $7.5M from Clal Biotechnology Industries and is supported by the Chief Scientist of Ministry of Industry and Trade of Israel. Polyheal relies on an innovative patented microsphere based method for the stimulation of wound healing and tissue regeneration. Activation of the cells involved in the healing process provides an effective technique for dealing with healing and regeneration problems resulting from chronic ulcers, trauma, injuries, bedsores, burns and surgery. Preliminary clinical trials were conducted using standard clinical trial conditions. All patients involved in the trial received the best available standard treatment before the trial. The patients who were treated for chronic ulcers had primary diagnoses that included NIIDM, Breast Cancer IIB, Bechet Disease, chronic drug dependence +DM, Rheumatoid Arthritis, Vascular Surgery,ÿ etc.ÿ Detailed analysis of this trial are not yet completed. In preliminary tests and trials a large number advantages over existing treatments have become apparent: • Meaningful reduction in the time required for healing; • Reduction in the prominence and size of scars; • Reduced pain from the wound; • Absence of immunological problems; • Non allergenic; • Clear anesthetic effect; • Non-toxic; • No side effects. Synergix Ltd. Contact Data Contact: Name: Dr. Ouri Fischel, Chief Operating Officer Address: Technology Park Malcha, Bldg.1 Jerusalem, Israel, 91487 Telephone: 972-2-6480397 Fax: 972-2-6480399 44
  45. 45. Email: info@drugdesign.com Web-site: www.drugdesign.com General Information Year established: 1996 Number of Employees: 7 Core business: Pharmaceuticals, Rational drug design Areas of activity: Therapeutics – Ethical, Platform Technologies, Bioinformatics Potential areas for collaboration: Investment, R&D, Marketing Overview/Products Synergix Ltd. is a drug design company specialized in the rational design of drugs. The company uses advanced and novel approaches to drug discovery based on rational drug design, synthetic chemistry and in-vitro testing of lead compounds for the pharmaceutical companies. Synergix Ltd. creates and develops small-molecule pharmaceuticals designed on the basis of their three-dimensional complementary features with biological macromolecules ( receptors, enzymes, etc.) The technology provides an exceptionally versatile route to new drugs and can be applied to virtually and target biological system. Synergix Ltd. is currently applying these technologies to the design and development of novel drugs for the treatment of cardiovascular diseases, central nervous system disorders, cancer. aids and other major diseases Tarom Applied Technologies Ltd. Contact Data Contact person: Mr. Zvi Barr, General Manager Address: 93 Jabotinsky St. Petach Tikva, Israel, 49517 Telephone: 972-3-9214145 Fax: 972-3-9214146 Email: tarom@tarom.co.il General Information Established: 1989 Ownership: Private Core business: Diagnostics. Biomedical Reagents 45
  46. 46. Overview/Products Tarom Applied Technologies, established in 1989, deals in manufacturing, sales and marketing of high quality biomedical reagents. The company's reagent lines include monoclonal antibodies developed at the Weizmann Institute - steroid hormones Estradiol 2F9, Progesterone 560.1 and many others, as well as more than 200 Recombinant Cytokines, Chemokines and the related monoclonal and affinity purified polyclonal antibodies. These products are aimed at the diagnostic industry. The company also offers a top quality range of biochemical products, inspected and approved for pharmaceutical manufacture as well as clinical and research laboratories. - Therapeutic Start-Ups - Advanced Nanoparticles Contact Data Contact person: Dr. Nava Epstein, CEO Address: Hitec - Har Hotzvim Technology Entrepreneurship Center, P.O.Box: 45010, Jerusalem, Israel, 91450 Telephone: 972-2-587-0710 Fax: 972-2-581-2386 Email: nepstein@inter.net.il General information Year established: 1999 Number of Employees: 4 Core business: Uniform, biodegradable and non-toxic magnetite nanoparticles. Areas of activity: Therapeutics – Ethical, Diagnostics Potential areas for collaboration: Investment, R&D, Marketing Overview/Products A new class of uniform, biodegradable and non-toxic magnetite (Fe3O4) nanoparticles has been prepared and characterized. The preparation process of these particles is simple, does not involve any toxic material and the yield is close to 100%. The particles are super- 46
  47. 47. paramagnetic, i.e., they magnetize in the presence of a magnetic field, but no remanence is observed in the absence of the magnetic field. Each magnetic nanoparticle is composed of a very thin organic nucleus (5-10%) and a thick shell of magnetite. Different techniques were established for coating these magnetite nanoparticles with several functional and biocompatible polymers. Both the coating and the magnetite production processes are controllable, so that it is possible to prepare particles with a specific size of each particle component as well as particles coated with protein ligands for tissue specific imaging applications. Magnetite nanoparticles have enormous potential applications in the biomedical as well as in non-biomedical fields. The company intends to initially focus on preparing contrast agents for magnetic resonance imaging (MRI) and ultrasound, the market for which is rapidly expanding. Allergene Ltd. Contact Data Contact person: Dr. Tamar Raz, General Manager Address: 2a Katzir St., Biomedical Incubator Rad-Ramot, Ramat Gan, Israel, 52656 Telephone: 9723-5312620 Fax: 972-3-5341650 Email: info@allergene.co.il Website: www.allergene.co.il General Information Year established: 1998 Number of Employees: 2 Core business: Anti-allergic compounds for skin allergies, Novel anti allergic drug. Areas of activity: Therapeutics – Ethical, Platform Technologies Potential areas for collaboration: Investment, R&D Overview/Products The company's mission is to develop novel anti-inflammatory and anti-allergic drugs. This development is based on an innovative concept of inhibiting the signal transduction pathways in mast cells, thereby blocking the secretion of inflammatory mediators. 47
  48. 48. As such, Allergene drugs will inhibit the allergic reaction at a very early stage and also prevent the whole range of delayed inflammatory reactions. Allergene products have a wide range of applications in the treatment and cure of all mast cell dependent, inflammatory diseases. These include asthma, conjunctivitis (allergic eye disease), rhinitis (hay fever), urticaria, inflammatory bowel diseases, migraine and more. ANS -Advance Neuroprotective Systems Ltd. Contact Data Contact person: Mr. Idan Harpaz, Managing Director Address: Blg.13A, Kiryat Weizmann Science Park, Incubator for Technological Entrepreneurship (ITEK), Ness Ziona, Israel, 74140 Telephone: 972-8-9409853 Fax: 972-8-9462523 Email: ansyst@netvision.net.il General Information Year established: 1998 Core business: Biomarkers for diagnosing predisposition to epilepsy and for monitoring anti-epileptic treatment. Areas of activity: Therapeutics, Diagnostics, and Platform Technologies Potential areas for collaboration: Investment, R&D, Marketing Overview/Products A.N.S. Ltd. is devoted to the research and development of a unique set of plasma and urine biomarkers, which indicate predisposition to epilepsy and provide information for improved monitoring of epilepsy treatment by anti-epileptic drugs. The data was obtained using animal models of genetic epilepsy (including a proprietary model) and from the clinical study started recently. Based on HPLC (High-Performance Liquid Chromatography) assay ANS has developed the specific markers indicative for predisposition to seizure disorders and to attention deficit disorder. A specific combination of markers is suggested for improved monitoring of epilepsy treatment with anti-epileptic drugs. 48
  49. 49. Applications of ANS technology: • Screening of patients at high risk of developing epilepsy, such as selected groups of children, patients after brain injury or intracranial infections, relatives of epileptic patients, pregnant women, among others. • In Vitro pre-symptomatic diagnosis of epilepsy aimed at the pathogenically determined preventive treatment of the disease. • Biochemical monitoring of antiepileptic drug therapy aimed to prevent overdosing or underdosing of antiepileptic drugs and turning the epilepsy into intractable forms. BioPreventive Ltd. Contact Data Contact person: Dr. Yoram Rubin, General Manager Address: Ramat Gabriel, P.O.Box: 536, Migdal Haemek, Israel, 23103 Telephone: 972-4-6442885/8 Fax: 972-4-6442886 Email: yrubin@biopreventive.com Website: www.biopreventive.com General Information Year established: 1998 Number of Employees: 10 Core business: Point-of-care diagnostic kits. Areas of activity: Therapeutics - Drug Monitoring, Diagnostics Potential areas for collaboration: Strategic Alliances, International Distribution Overview/Products Biopreventive Ltd. is a biotechnology research and development company, which is developing a series of innovative diagnostic kits, indicating the accumulation of Disease Specific Alarming Biomarkers (DSABM), to provide medical decision-makers with rapid, sophisticated and accurate point-of-care diagnostic tools for early detection of acute life- threatening diseases. The tests are non-invasive, inexpensive and easily administered. 49
  50. 50. The company's first family of products is designed for the detection of coronary heart disease. BioSilk Ltd. Contact Data Contact person: Iris Hochman, General Manager Address: P.O.B. 12, Katzrin 12900 Telephone: 972-6-6964212 Fax: 972-6-6962564 E -Mail: bio-silk@canaan.co.il General Information: Year established: 1998 Number of Employees: 3 Areas of activity: Therapeutics, Cosmetics Potential areas for collaboration: Investments Overview/Products The company is developing a series of products that are intended for the treatment and prevention of scars on wound, surgery, burn or cosmetic treatment sites. The product is based on a polymer that slowly releases a mixture of enzymes and optional medication onto the treated area. The product can be adapted to the treated area and can treat large areas over a greater time period. The characteristics of polymer, the medication and the structure of the product (an adhesive bandage which is protected externally), ensure simplicity of use, long self -life and effective scar prevention. Biota Ltd. Contact Data Contact person: Mr. Meir Haber, General Manager Address: TEIC - Technological Incubator, P.O.Box: 212, Nesher, Israel, 36601 Telephone: 972-4-8308352 Fax: 972-4-8210531 50
  51. 51. Email: meir@algawish.com Website: www.algawish.com General Information Year established: 1999 Number of Employees: 2 Core business: Tissue adhesives for surgery. Areas of activity: Therapeutics - Ethical Potential areas for collaboration: Investments, R&D, Marketing Overview/Products Biota Ltd. was established to develop and commercialize tissue adhesives (Tas) made from proprietary algae derived materials for the modern surgical arena. Can-Fite Biopharma Ltd Contact Data Contact person: Dr. Ilan Cohn, President Address: Reinhold Cohn House, P.O.Box: 4060, Tel Aviv, Israel, 61040 Telephone: 972-3-7109330 Fax: 972-3-5606405 Email: dieliasoof@rcip.co.il General Information Core business: Cancer therapeutic technology that makes use of adenosine receptor agonists. Overview/Products Can-Fite BioPharma Ltd. is a biopharmaceutical company that develops novel anti-cancer therapies. The Company's proprietary technology is based on a clinical observation that cancer almost never metastasises into skeletal muscles. In an attempt to decipher the root of this phenomena, Can-Fite's scientists discovered a group of molecules of a small molecular mass, which target the A3-adenosine receptor, and which yield their effect through a unique signal transduction pathway. Can-Fite's drugs are agonists of the A3 adenosine receptor. The drugs that are being developed have two types of activities. They inhibit proliferation of cancer cells through a cytostatic mechanism which specific towards tumour cells and have no such effect on non- 51
  52. 52. tumorous cells. They also protect white blood cells and bone marrow cells from the cytotoxic effects of chemotherapy through the induction of the growth factor G-CSF (granulocyte-colony stimulating factor). Additionally, the drugs also act in combination with chemotherapy to yield a more pronounced anti-cancer effect. Remarkably, the Company's drugs achieve these effects through oral administration. Can-Fite's leading drug, AFite is a highly potent drug and exerts its therapeutic effects at a dose of 3-10 mg/KG body weight. Can-Fite's leading drug, AFite, is currently undergoing pre-clinical GLP studies. AFite will be developed initially as an adjunct to chemotherapy for the purpose of countering nutropenia, a major toxic side effect of chemotherapy. CardImmune Ltd. Contact Data Contact person: Dr. Emmanuel Elalouf, Manager Address: 3 Habosem St., Kiryat Hamada, P.O.Box: 15212, Ashdod, Israel, 77051 Telephone: 972-8-8536050 Fax: 972-8-8536052 Email: emmanuel@eager.co.il Website: www.cardimmune.com General Information Year established: 2000 Areas of activity: Therapeutics Core business: Therapeutics, Pharmaceuticals Overview/Products CardImmune Ltd. develops innovative drugs for prevention and/or treatment of therosclerosis. The approach is based on specific modulation of the immune response so as to reduce accumulation of plaques in the arteries. 52
  53. 53. Carmel Biosensors Ltd Contact Data Contact person: Mr. Boaz Kaplan, Vice President Address: MATAM, Bldg 20, Haifa, Israel, 31905 Telephone: 972-4-8550850 Fax: 972-4-8550857 Email: yoram@carmel-biosensors.com General Information Established: 1993 Employees: 30 Core business: Sensors for medical use, designed to provide continuous, real time monitoring of key body constituents, such as glucose level, Oxygen, Carbon Dioxide, hormones, drugs and anesthetic agents. Main Markets: Hospitals & Diabetics Overview/Products Carmel Biosensors Ltd. is developing a technology designed to result in a family of novel wearable sensors to provide continuous monitoring of the Blood Glucose Level (BGL) of diabetics. This technology promises to greatly improve the quality of life and longevity of diabetics, a community numbering more than 30 million in the western world, while significantly reducing their treatment costs. Following extensive work on experimental animals, Carmel began human clinical trial in Israel at the end of 1997. The results of these preliminary trials are encouraging, and Carmel is preparing itself to trials that are more comprehensive. Presently Carmel is in the process of acquiring a small company that uses the same technology to provide continuous monitoring of the blood levels of additional constituents, such as gases, hormones and drugs. Carmel has demonstrated a prototype sensor that measures the BGL by analyzing the signals generated by a single animal-derived islet enclosed in a biocompatible probe. In its productive form, the disposable sensor-probe, which is comparable in diameter to a single human hair, will be part of a self-adhesive skin patch. • Carmel's initial product, the GlucAlarm, is intended for diabetics for whom low BGL - hypoglycemia - poses a serious threat. The GlucAlarm patch will provide 53
  54. 54. early warning of impending hypoglycemia, giving the patient sufficient time to avert the condition by ingesting sugar. • Carmel's second product, GlucoGuard, is intended for all Type-I and a large percentage of Type-II diabetics. It will continuously display the BGL by means of a watch-like device. At a later stage, Carmel intends to combine its sensor with an insulin delivery system to form a complete BGL control system, the optimal diabetes treatment. Chelotech Ltd. Contact Data Contact person: Prof. Max Herzberg, General Manager Address: 3 Habosem St., P.O.B. 15212, Ashdod 252051 Telephone: 972-8-8536050 Fax: 972-8-8536052 General Information Areas of activity: Therapeutics Overview/Products Develops technology allowing the inhabitation of free radicals generation. The technology is based on the use of metal chelators that strongly bind iron and cooper but do not bind calcium or magnesium. Colbar R&D Ltd Contact Data Contact person: Mr. Itay Itzhaky, CEO Address: 10 Hashomron St. Ramat Hasharon, Israel, 47203 Telephone: 972-3-5470804 Fax: 972-3-5470944 Email: colbar@colbar.co.il General Information Established: 1995 Employees: 30 54
  55. 55. Core business: Guided-tissue regeneration applications in orthopaedics and dentistry and injectable collagen for wrinkle augmentation and treatment of incontinence. The technology enables collagen to be created with a controllable rate of degradation that can vary from weeks to years. Overview/Products Colbar has developed a unique technology for the production of collagen-based products. Col-Bar's line of products, intended for medical and cosmetic applications, offers a higher degree of safety and a more controlled rate of biodegradation than existing collagen products on the market. Colbar develops, produces and markets innovative products in the field of tissue engineering based on the cutting-edge technology of cross-linked collagen protein. This new technology allows for the development of a range of products and applications in various areas of medicine such as orthopedics, urology and dentistry as well as in cosmetic surgery. During 2000, Colbar received both FDA and CE approvals to market its first product - the Dental Membrane. The company will soon be entering the US, European and Far Eastern markets with the help of 3I Implants, a leading manufacturer and worldwide marketer of oral reconstructive products and dental implants. Collgard Biopharmaceuticals Ltd Contact Data Name: Dr. Shay Yarkoni, R&D & General Manager Israel Address: 1b Bazel St. Petach Tikva, Israel, 49170 Telephone: 972-3-9247447 Fax: 972-3-9247446 Email: yarkoni@collgard.com Website: www.collgard.com General Information Established: 1996 Parent: Medica L.P. Employees: 11 Core business: Collgard is dedicated to developing products for the treatment of the following diseases: cancer, restenosis, fibrosis and autoimmune diseases. 55
  56. 56. Overview/Products Collgard Biopharmaceuticals Ltd. is a privately held company founded in 1996. The company leverages third party relationships with key scientific and medical consultants and collaborators for the advanced development of its clinical programs. Collgard develops unique therapeutic products that affect the turnover of collagen to prevent or treat scleroderma, solid tumors, restenosis and other fibrotic disorders. The Company's lead product development programs are based on the application of Halofugione, a specific inhibitor of collagen type I synthesis and collagenase. Collgard's program for the treatment scleroderma is in phase II clinical development. The Company expects to initiate additional scleroderma and cancer clinical studies with Halofuginone in the beginning of year 2000. Collgard scientists have demonstrated Halofuginone, a compound with a history of veterinary use, has promising activity in a variety of disorders in which "tissue trauma" and collagen turnover play an essential role. Columbine Ventures Contact Data Contact person: Mrs. Nava Swersky Sofer, Managing Director Address: 50 Dizengoff St., Top Tower, 22 floor, Tel Aviv, Israel, 64332 Telephone: 972-3-6209010 Fax: 972-3-6209011 Email: bracha@columbinevc.com Website: www.columbinec.com General Information: Established: 1997 Employees: 5 Core business: Therapeutics: Ethical; Immunological products for the treatment of cancer. Overview/Products Columbine Ventures is an early-stage venture firm investing in the biomedical field, including biotechnology, therapeutics, medical devices, bio-informatics and diagnostic technologies. Columbine Ventures focuses on Israeli and Israel-related companies. Columbine Ventures 's management team offers expertise in strategic management, 56
  57. 57. corporate and business development, scientific and clinical research, medicine and finance. Columbine Ventures seeks novel technologies and solutions to unmet medical needs and work with inventors and entrepreneurs to ensure the most efficient scientific and commercial development, and the best chance for success. Common Sense Ltd Contact Data Contact person: Mr. Menashe Terem, Managing Director Address: 7 Haeshel St., Zone 2, Caesarea Industrial park, P.O.Box: 3567, Caesarea, Israel, 38900 Telephone: 972-4-6277101 Fax: 972-4-6277103 Email: comsensm@inter.net.il General Information Established: 1999 Employees: 6 Core business: Instant diagnosis of vaginal diseases Overview/Products Common Sense Ltd. is specializing in diagnostic tools. The company's first product, the Diagnostic Absorbent Pad (DAP) will enable the detection and treatment of infectious diseases at a very early stage. Coraltis Ltd Contact Data Contact person: Mr. Yossi Bornstein, CEO Address: P.O.Box: 168, Rosh Haayin, Israel, 48091 Telephone: 972-3-9022955 Fax: 972-3-9022954 Email: yossi@coraltis.co.il General Information 57
  58. 58. Established: 1997 Core business: Therapeutically-sound nutraceuticals and proprietary polymer-based delivery systems Overview/Products Coraltis Ltd. is a newly formed company comprising two fully dedicated business units called "Caretec" and "Coraltis", both active in the fields of developing therapeutically- sound nutraceuticals and proprietary polymer-based delivery systems. "Caretec" focuses on the administration and commercialization of the versatile amino acid L-Arginine in therapeutic dosages using its unique and proprietary taste masking micro encapsulation technology. To date, the Company has developed and designed a targeted product line that is already being marketed in Israel and is ready for international penetration to the global nutraceutical market. "Coraltis" specializes in enabling players in the nutraceutical industries with a novel pulsatile delivery platform for new and established compounds. "Coraltis"' mission is to establish its Multi Pulse Delivery (MPD) System as the leading delivery platform for maximizing the absorption rate and therapeutic value of active ingredients, nutraceutical and eventually pharmaceutical worldwide using a single-dose formula. Curetech Ltd Contact Data Contact person: Dr. Britta Hardy, Manager Address: 3 Azrieli Center, The Triangular Tower, 45th Fl. Tel Aviv, Israel, 67023 Telephone: 972-3-6075733 Fax: 972-3-6075734 Email: brittah@netvision.net.il Website: www.cbi.co.il/curetech General Information Parent: Clal Biotechnology Industries Ltd. Core business: Genetic engineering cancer therapy. Overview/Products 58
  59. 59. Curetech Ltd. is developing a new family of immunotherapy products to fight cancer diseases for which there is no cure or adequate treatment. Curetech's lead product, "BAT" is a monoclonal antibody (mAb) raised against a Daudi B-lymphoblastoid cell-line. BAT mAb exhibits unique immune stimulatory and anti-tumor properties culminating in destruction of tumor cells. More specifically, since BAT's anti-tumor mechanism is mediated via activation of the immune system, it can be applied against a panel of different tumor types. BAT mAb development program is in advanced stages of preclinical trials, and it is expected to enter its first Phase I clinical trial approximately in Q1 2003. Recently, Curetech has completed a critical milestone in BAT's clinical development and preparation for human clinical trial - the humanization process of BAT. In this process the mouse mAb is modified genetically into a fully human mAb in order to maximize BAT efficacy in humans. Curetech has a promising research and development program designed to expand its platform technology. One of these second-generation products is an anti-cancer vaccine based on BAT's antigen (the antigen to which BAT mAb binds). DexCell Pharma Ltd Contact Data Contact person: Mr. Dan Oren, President Address: 7 Hamarpeh St. Har Hotzvim, P.O.Box: 23950, Jerusalem, Israel, 91239 Telephone: 972-2-5898211 Fax: 972-2-5812722 General Information Established: 1988 Parent: Dexxon Ltd. Employees: 72 Turnover (1996): U.S. $ 3,2 M Core business: Controlled release drug delivery systems for oral health care Overview/Products DexCell Pharma Ltd. (former Perio Products Ltd.) is engaged in the development and manufacture of novel drug delivery systems for the targeted controlled release of 59
  60. 60. pharmaceuticals. DexCell Pharma's proprietary technologies are primarily based on degradable polymers which can be mixed with active ingredients and modified to: • Degrade over a designated period of time ranging from hours to weeks; • Be released in a specified part of the body. DexCell Pharma has developed four distinct technologies - The PerioChip, the Colonic Delivery System (CDS), the Liquid Polymer technology, and the SLP - and has a number of formulations under development incorporating these technologies. These technologies provide significant advantages over existing controlled release drug delivery systems as well as conventional oral and injectable methods of drug delivery by increasing efficacy, safety, bioavailability and patient compliance and comfort. DexCell Pharma aggressively protects its proprietary technologies by filing for and maintaining patents in the United States, Europe and other countries throughout the world. DigoPharm Contact Data Contact person: Dr. Tami Bar, CEO Address: 7 Haofe St., Ashkelon Technological Industries - Tech. Incubator, P.O.Box: 7284 Ashkelon, Israel, 78172 Telephone: 972-8-6510041 Fax: 972-8-6510581 Email: baret@isdn.net.il General Information Established: 2000 Type: Start-up company within Technological Incubator Parent: Ashkelon Technological Industries - ATI Core business: New pharmaceuticals for treating cardiovascular diseases Overview/Products 60
  61. 61. DigoPharm Ltd. is an Israeli company dedicated to the discovery and development of drugs for human diseases by modulating the essential cellular enzyme Na+,K+-ATPase existing in every living cell. DigoPharm's novel compounds will serve as a starting point for the development of drugs to treat cardiac diseases and other human diseases such as cancer and neurological disorders. DigoPharm's novel compounds are based on the isolation and identification of natural endogenous group of molecules - 19-norbufadienolides - and their synthetic derivatives. These compounds can allow in the first time modulation of the Na+,K+-ATPase enzyme that exist in every human cell, using compounds based on endogenous human molecules. DigoPharm's novel 19-bufaline-based compounds are primarily targeted to treat cardiovascular diseases. Heart failure is not a specific disease, but a clinical syndrome developed as a result of the heart's inability to meet the oxygen and nutritional demands of the body. DigoPharm has already performed various most successful trials in vitro as well as on animal models, indicating the efficacy and safety of its compounds. The Company anticipates that upon successful achievements of its primary objectives it will be ready and attractive for corporate partnerships with leading pharmaceutical companies. Dittekol Ltd Contact Data Contact person: Mr. Yair Cohen, CEO Address: 7 Haofe St., Ashkelon Technological Industries - Tech. Incubator, P.O.Box: 7284 Ashkelon, Israel, 78172 Telephone: 972-8-6711852 Fax: 972-8-6711855 Email: ati@ati.co.il General Information Established: 2002 Parent: Ashkelon Technological Industries - ATI Core business: Novel Bilayer Collagen-based dressing 61

×